Header Logo

Connection

Doris Benbrook to Disease-Free Survival

This is a "connection" page, showing publications Doris Benbrook has written about Disease-Free Survival.
Connection Strength

0.193
  1. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
    View in: PubMed
    Score: 0.087
  2. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol. 1997 Jun; 65(3):425-9.
    View in: PubMed
    Score: 0.035
  3. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43.
    View in: PubMed
    Score: 0.028
  4. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):377-82.
    View in: PubMed
    Score: 0.026
  5. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 May; 105(2):508-16.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.